The n-Lorem Foundation, a nonprofit organization dedicated to providing support and solutions for individuals afflicted with nano-rare diseases, has recently forged a significant partnership with Hongene Biotech Corporation. This collaboration aims to bolster n-Lorem’s ongoing mission of developing and delivering personalized experimental antisense oligonucleotide (ASO) medications to nano-rare disease patients worldwide, completely free of charge and for the duration of their lives.
Nano-rare diseases are characterized by their extreme rarity, affecting only a handful of individuals globally, typically numbering between one to thirty patients. These conditions often pose unique challenges due to their limited understanding, lack of available treatments, and the substantial barriers to developing therapies tailored to such specific genetic mutations.
In this groundbreaking partnership, Hongene Biotech Corporation, a global leader specializing in nucleic acid raw material supply and contract development and manufacturing organization (CDMO) services, has committed to supporting n-Lorem’s efforts by providing vital compounds known as amidites. These amidites are essential components in the development process of ASO medicines, enabling the targeted modulation of gene expression to address the underlying genetic abnormalities responsible for nano-rare diseases.
By furnishing these crucial materials, Hongene aims to alleviate the financial burden associated with ASO medicine development, thereby enabling n-Lorem to extend its support to a larger cohort of nano-rare disease patients. Specifically, Hongene’s contribution will facilitate the development and evaluation of ASO therapies for up to twenty nano-rare patients, significantly expanding the reach and impact of n-Lorem’s pioneering initiatives.
Dr. Stanley T. Crooke, esteemed Chairman, Founder, and CEO of the n-Lorem Foundation, underscored the profound significance of this collaboration in offering hope and tangible solutions to individuals grappling with nano-rare diseases. He emphasized that n-Lorem’s unique approach enables the tailored design and production of ASO medicines, precisely targeting each patient’s distinct genetic mutation, thereby offering a beacon of hope to those who would otherwise face the bleak prospect of progressive disease without viable treatment options.
Expressing pride in their partnership with n-Lorem, Mr. Wei Jiang, Founder and Chief Executive Officer of Hongene Biotech Corporation, reiterated the company’s unwavering commitment to making nucleic acid medicines universally accessible. He emphasized that Hongene’s expertise in nucleic acid manufacturing and supply positions them as a valuable asset in furthering n-Lorem’s mission of delivering life-changing therapies to nano-rare disease patients worldwide.
This collaboration between n-Lorem and Hongene Biotech Corporation represents a pivotal step forward in the quest to address the unmet needs of individuals afflicted with nano-rare diseases. By combining expertise, resources, and a shared commitment to innovation and patient-centric care, this partnership holds the promise of unlocking new avenues of treatment and hope for those navigating the complexities of these exceptionally rare and challenging conditions.
